These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37290029)

  • 1. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
    Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
    J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Potential Urologic Prescription Drug Savings With Mark Cuban Cost Plus Drug Company.
    Schloegel V; Harris L; Harris A; Dropkin B
    Urol Pract; 2024 Mar; 11(2):276-282. PubMed ID: 38377158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug Program.
    Gulati S; Gupta M; Yan T; Yelamanchili S; Xu LQ; Bharani T; Naji A; Agarwal D
    Pharmacoeconomics; 2024 Nov; 42(11):1279-1286. PubMed ID: 39167355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model.
    Bouvette MJ; Lam AB; Bouvette C; Ayanambakkam A; Nipp RD
    Oncologist; 2024 Jul; 29(7):e918-e921. PubMed ID: 38739017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability and Pricing of Drugs Prescribed by Otolaryngologists Through a Direct-to-Consumer Pharmacy: Medicare Savings Implications.
    Erickson TS; Pletcher SD; Soler ZM; Schlosser RJ; Workman AD; Rathi VK
    Otolaryngol Head Neck Surg; 2024 Oct; ():. PubMed ID: 39413315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model.
    Narendrula A; Lang J; Mossialos E
    Front Pharmacol; 2023; 14():1179253. PubMed ID: 37727389
    [No Abstract]   [Full Text] [Related]  

  • 8. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.
    Lalani HS; Kesselheim AS; Rome BN
    Ann Intern Med; 2022 Jul; 175(7):1053-1055. PubMed ID: 35724381
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
    Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
    Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies.
    Lalani HS; Tessema FA; Kesselheim AS; Rome BN
    J Gen Intern Med; 2024 Sep; 39(12):2187-2195. PubMed ID: 38321315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities.
    Shapiro K; Dusetzina SB; Brucker BM; Escobar CM
    Urology; 2024 Jan; 183():57-62. PubMed ID: 37778479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
    Campbell D; Blazer M; Bloudek L; Brokars J; Makenbaeva D
    Am Health Drug Benefits; 2019 Nov; 12(7):333-342. PubMed ID: 32055281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Cost Savings in Medicare Part D Across Gastroenterology: An Assessment of Alternative Drug Sourcing.
    Bouvette CA; Bouvette M; Yohannan B; Rumman A; Ali I
    Am J Gastroenterol; 2024 Apr; 119(4):764-767. PubMed ID: 38084855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare Part D Payments for Generic Imatinib From 2017 to 2023.
    Dusetzina SB
    JAMA Intern Med; 2024 Jan; 184(1):104-105. PubMed ID: 37983024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.